On March 8, 2022 CytoImmune Therapeutics, a clinical-stage immunotherapy company developing a novel class of natural killer cell-based cancer therapies, reported that the company will present preclinical data from its FLT3 CAR-NK cell program for acute myeloid leukemia and its TRACK-NK program for non-small cell lung cancer at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, CytoImmune Therapeutics, MAR 8, 2022, View Source [SID1234609714]). The meeting is being held April 8-13, 2022, in New Orleans.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
CytoImmune is leveraging proprietary, robust and well-characterized NK cell expansion and engineering technologies to advance its tumor-reactive natural killer (TRACK-NK) cell therapies for patients with cancer. The cells are engineered to directly attack cancer cells and broadly stimulate both the innate and adaptive arms of the immune system through IL-15 secretion, enabling the potential for potent and specific tumor killing.
"The pioneering work of our founders has enabled the creation of dual-mechanism immunotherapy agents that have the potential to treat a broad range of cancers, including difficult to treat cancers such as AML and NSCLC," said Christina Coughlin, M.D., Ph.D., Chief Executive Officer of CytoImmune. "We look forward to presenting updated data from two of our NK-cell based programs, which we believe further support their potential to offer best-in-class NK cell activation with broad immune stimulation for the treatment of patients with solid tumors or hematologic malignancies."
Abstract Title: LB102. Off-the-shelf cord blood FLT3 CAR-NK cells for immunotherapy of acute myeloid leukemia
Session: Late-Breaking Research: Immunology 1
Session Date & Time: Monday, April 11, 2022, from 1:30p.m. to 5:00p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 18
Abstract Title: LB211. Tumor-reactive and anti-PD-L1 co-stimulated killer cells (TRACK-NK) for immunotherapy of non-small cell lung cancer
Session: Late-Breaking Research: Immunology 2
Session Date & Time: Wednesday, April 13, 2022, from 9:00a.m. to 12:30p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 18